• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 4 Health Care Stocks That Are Preparing To Pump This Month

    6/5/24 7:46:52 AM ET
    $A
    $EXAS
    $INBX
    $TDOC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care
    Get the next $A alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

    Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

    Inhibrx Biosciences, Inc. (NASDAQ:INBX)

    • On May 24, Inhibrx stockholders approved sale of INBRX-101 to Sanofi. The company's stock fell around 50% over the past five days and has a 52-week low of $12.95.
    • RSI Value: 15.08
    • INBX Price Action: Shares of Inhibrx Biosciences fell 4.5% to close at $17.21 on Tuesday.
    • Benzinga Pro's real-time newsfeed alerted to latest INBX news.

    Exact Sciences Corporation (NASDAQ:EXAS)  

    • On May 8, Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, according to Benzinga Pro. The company reported a quarterly loss of 60 cents per share, which missed analyst estimates for a loss of 48 cents per share. "The Exact Sciences team is off to a strong start again in 2024. Our team delivered more than a million Cologuard and Oncotype DX test results to patients and advanced our deep pipeline of life-changing cancer diagnostics," said Kevin Conroy, chairman and CEO of Exact Sciences. The company's stock fell around 31% over the past month. It has a 52-week low of $43.30.
    • RSI Value: 27.83
    • EXAS Price Action: Shares of Exact Sciences fell 3.1% to close at $43.45 on Tuesday.
    • Benzinga Pro's charting tool helped identify the trend in EXAS stock.

    Teladoc Health, Inc. (NYSE:TDOC)

    • On April 25, Teladoc Health posted mixed quarterly results. “We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter,” said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. The company's stock fell around 15% over the past month and has a 52-week low of $10.85.
    • RSI Value: 28.75
    • TDOC Price Action: Shares of Teladoc Health fell 1.9% to close at $10.87 on Tuesday.
    • Benzinga Pro's signals feature notified of a potential breakout in Teladoc Health’s shares.

    Agilent Technologies, Inc. (NYSE:A)

    • On May 29, Agilent Technologies posted mixed second-quarter financial results. Agilent also revised its full-year outlook to reflect a slower market recovery. "In Q2, we delivered on our expectations and showed the resiliency of our diversified business. While we see the market improving, it is improving at a slower pace than anticipated," said Padraig McDonnell, president and CEO of Agilent. The company's shares lost around 12% over the past five days. The company's 52-week low is $96.80.
    • RSI Value: 29.45
    • A Price Action: Shares of Agilent fell 0.4% to close at $130.85 on Tuesday.
    • Benzinga Pro's earnings calendar was used to track Agilent’s upcoming earnings report.

    Now Read This: Dollar Tree, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Wednesday

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $EXAS
    $INBX
    $TDOC

    CompanyDatePrice TargetRatingAnalyst
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Teladoc Health Inc.
    $TDOC
    12/9/2025$8.50Equal Weight
    Barclays
    More analyst ratings

    $A
    $EXAS
    $INBX
    $TDOC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teladoc upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Teladoc from Hold to Buy and set a new price target of $11.00

    3/10/26 8:39:03 AM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc upgraded by BofA Securities with a new price target

    BofA Securities upgraded Teladoc from Neutral to Buy and set a new price target of $7.00

    2/26/26 12:11:08 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EXAS
    $INBX
    $TDOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

    Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice Agilent Technologies Inc. (NYSE:A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories. At USCAP 2026, Agilent will feature its continued expansion in oncology

    3/19/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

    The Oncodetect® test expands the role of tumor-informed MRD in triple-negative breast cancer The Cancerguard® test demonstrates improved early-stage multi-cancer detection performance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze trial evaluating its tumor-informed circulatin

    3/17/26 4:31:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

    Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics' CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides cus

    3/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EXAS
    $INBX
    $TDOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by President, U.S. Group Health Bliss Kelly

    4/A - Teladoc Health, Inc. (0001477449) (Issuer)

    3/12/26 4:06:42 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    CHIEF EXECUTIVE OFFICER Divita Charles Iii converted options into 64,653 shares and sold $152,243 worth of shares (27,731 units at $5.49), increasing direct ownership by 11% to 364,784 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    3/12/26 4:06:12 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    EVP, Human Resources Condella Sarah covered exercise/tax liability with 1,913 shares and exercised 3,900 shares at a strike of $5.03, increasing direct ownership by 2% to 131,121 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/3/26 7:16:13 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $A
    $EXAS
    $INBX
    $TDOC
    SEC Filings

    View All

    SEC Form 144 filed by Teladoc Health Inc.

    144 - Teladoc Health, Inc. (0001477449) (Subject)

    3/11/26 3:35:25 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/6/26 4:05:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/3/26 4:17:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EXAS
    $INBX
    $TDOC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Director Kayyem Jon Faiz bought $1,523,620 worth of shares (107,186 units at $14.21) (SEC Form 4)

    4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)

    11/22/24 4:03:55 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $A
    $EXAS
    $INBX
    $TDOC
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    AR/VR is Revolutionizing Medical Education & Training While Transforming Healthcare Industry

    NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- MarketNewsUpdates News Commentary A recent report from ResearchAndMarkets said that the U.S. augmented reality and virtual reality in healthcare market size which was estimated at USD 1.03 billion in 2024 is projected to grow at a CAGR of 15.4% from 2025 to 2030. It said that advancements in healthcare IT infrastructure and increased venture capital investment, fueled by numerous start-ups and government programs such as NIH and FDA initiatives, support AR/VR research. In addition, the declining cost of head-mounted devices, rising demand from telemedicine, chronic disease care, and minimally invasive surgery, and integration with AI and 5G tech

    10/28/25 9:00:00 AM ET
    $GPRO
    $QCOM
    $TDOC
    Industrial Machinery/Components
    Consumer Discretionary
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $A
    $EXAS
    $INBX
    $TDOC
    Financials

    Live finance-specific insights

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Teladoc Health Reports Fourth Quarter and Full Year 2025 Results

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ("Full Year 2024"). Highlights Fourth Quarter 2025 revenue of $642.3 million, flat year-over-year, and Full Year 2025 revenue of $2,530.0 million, down 2% year-over-yearFourth Quarter 2025 net loss of $25.1 million, or $0.14 per share, and Full Year 2

    2/25/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc Health Appoints Michael Smith, Experienced Insurance and Financial Services Executive, to Its Board of Directors

    NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Michael Smith to its board of directors. With more than three decades of leadership experience in financial management and strategic transformation, Mr. Smith brings a deep understanding of long-term business sustainability within highly regulated, global markets. He joins the board following the previously announced retirements of Eric Evans and Thomas McKinley and will serve on the board's audit and nominating and corporate governance committees. "Michael's experience leading enterprise transformations makes him a strong addition to the Board," sa

    2/18/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $A
    $EXAS
    $INBX
    $TDOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inhibrx Biosciences Inc.

    SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)

    11/14/24 8:14:25 PM ET
    $INBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials